Drugs / SIPS-2209-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05787873 | Aug → Sep 2022 | — | Samik Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIPS-2209-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05787873 ↗ |
| Route | Oral | “SIPS-2209-2, SIPS-2209-3 - A single oral dose of 2 tablets under fasting condition” NCT05787873 ↗ |